Phimosis: A rare complication of immunotherapy with durvalumab

Jorge Arturo Alatorre Alexander - INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS

Phimosis : a rare complication of immunotherapy with durvalumab

Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

Analysis of phimosis referrals by primary physician type

233807 PDFs Review articles in SKIN DISEASES

Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy

Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial - The Lancet Oncology

Human aging Leaders in Pharmaceutical Business Intelligence (LPBI) Group

673662 PDFs Review articles in DOSING

Luis VÁZQUEZ-LAVISTA, Medical Doctor, Médica Sur Clinic Foundation, Mexico City, Urology / kidney transplant

Immunotherapy combo fails to extend disease-free survival in high-risk kidney cancer